Stocknear Logo Stocknear
/
Popular
Login

Evolus Inc.

13.03
0.00 (0.00%)
At close: Mar 24, 2025, 3:59 PM
12.90
-0.98%
After-hours: Mar 24, 2025, 06:39 PM EDT
0.00%
Bid 12.69
Market Cap 828.22M
Revenue (ttm) 274.26M
Net Income (ttm) -51.93M
EPS (ttm) -0.81
PE Ratio (ttm) -16.08
Forward PE 656.67
Analyst Buy
Ask 13.11
Volume 430,389
Avg. Volume (20D) 804,715
Open 13.09
Previous Close 13.03
Day's Range 12.68 - 13.18
52-Week Range 9.25 - 17.82
Beta 1.28

About EOLS

Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California....

[Show more]
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
IPO Date Feb 8, 2018
Employees 332
Stock Exchange NASDAQ
Ticker Symbol EOLS
Website https://www.evolus.com
Full Company Profile

Analyst Forecast

According to 4 analyst ratings, the average rating for EOLS stock is "Buy." The 12-month stock price forecast is $25, which is an increase of 91.94% from the latest price.

Stock Forecasts

Next Earnings Release

Evolus Inc. is scheduled to release its earnings on May 6, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
1 month ago
+5.47%
Evolus shares are trading higher after the company... Unlock content with Pro Subscription
2 months ago
+28.26%
Evolus shares are trading higher after the company announced it expects FDA approval for Evolysse gels within 90 days and is eyeing a Q2 2025 rollout in the US. Additionally, the company reported Q4 and FY24 revenue results and provided FY25 guidance.
news image

4 days ago · businesswire.com

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of 29,763...

news image

2 weeks ago · seekingalpha.com

Evolus, Inc. (EOLS) Q4 2024 Earnings Call Transcript

Evolus, Inc. (NASDAQ:EOLS ) Q4 2024 Earnings Conference Call March 4, 2025 4:30 PM ET Company Participants Nareg Sagherian - VP and Head of Global IR and Corporate Communications David Moatazedi - Pre...

news image

3 weeks ago · zacks.com

Evolus, Inc. (EOLS) Q4 Earnings and Revenues Lag Estimates

Evolus, Inc. (EOLS) came out with quarterly earnings of $0.01 per share, missing the Zacks Consensus Estimate of $0.06 per share. This compares to loss of $0.14 per share a year ago.

news image

3 weeks ago · reuters.com

Evolus posts quarterly profit on strong sales of cosmetic injection

Cosmetic drugmaker Evolus reported a fourth-quarter profit versus a year-ago loss on Tuesday, on strong demand for its wrinkle treatment Jeuveau which competes with Botox.

news image

3 weeks ago · businesswire.com

Evolus Reports Record Fourth Quarter and Full-Year 2024 Financial Results; Reaffirms 2025 Guidance

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced its financial results for the fourth ...

news image

1 month ago · businesswire.com

Evolus to Participate in the TD Cowen 2nd Annual Glowing Ahead: Beauty & Wellness Summit

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that members of its management team w...

news image

1 month ago · businesswire.com

Evolus to Report Fourth Quarter and Year End 2024 Results on March 4, 2025

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will repor...

news image

1 month ago · zacks.com

Evolus (EOLS) Moves 5.5% Higher: Will This Strength Last?

Evolus (EOLS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

news image

1 month ago · reuters.com

US FDA approves Evolus' anti-wrinkle gels

Evolus said on Thursday the U.S. Food and Drug Administration has approved its two new anti-wrinkle injectable gels, expanding the company's product portfolio beyond its cosmetic injection Jeuveau.

news image

1 month ago · businesswire.com

Evolus Announces FDA Approval of Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that the U.S. Food and Drug Administr...

Create Price Alert on EOLS

Your price alert will notify you when the stock price is above 13.03.

Add to Watchlist